Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Prenetics Global Ltd(PRE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PRE
09/15/2026: PRE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Prenetics Global Ltd is a specialized health-tech company that provides consumer genetic testing and diagnostic services, primarily in Asia. Its main strength lies in its CircleDNA platform, which leverages proprietary data to offer personalized wellness insights. The primary growth opportunity involves expanding these services through insurance and clinical partnerships. However, the company faces significant risks, including intense competition from global diagnostic giants and the challenge of establishing sustained profitability after the decline of pandemic-related testing revenues. Prenetics is generally best suited for growth-oriented investors who can tolerate high volatility and uncertainty, and they should monitor the adoption rate of its diagnostic platforms and ongoing cash management.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company operates in a high-growth sector but faces significant execution and profitability hurdles. |
| Momentum investor | Weak fit | Current stock performance does not signal sustained upward momentum. |
| Value investor | Weak fit | The lack of consistent profitability makes valuation difficult to justify on traditional metrics. |
| Dividend investor | Weak fit | The company is in a growth phase and does not pay a dividend. |
| Low-risk investor | Weak fit | High volatility and operational uncertainty make this unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large price swings due to its growth-stage nature and thin liquidity. |
| Valuation risk | High | Valuation remains disconnected from traditional earnings-based multiples. |
| Competition risk (Genomics/Diagnostics) | Medium / high | The company competes with established giants in both consumer genomics and laboratory services. |
| Business quality | Medium | While technology is innovative, the business model is still proving its long-term viability. |
| Dividend income | Low / none | There is no income generation for investors. |
| Execution risk | High | Success depends on scaling consumer health products profitably in diverse geographic markets. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 3.13% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 404.72M USD | Price to earnings Ratio - | 1Y Target Price 35.17 |
Price to earnings Ratio - | 1Y Target Price 35.17 | ||
Volume (30-day avg) 243.1K shares | Beta 0.31 | 52 Weeks Range 10.20 - 27.24 | Updated Date 09/15/2026 |
52 Weeks Range 10.20 - 27.24 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.46 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Consumer Genomics | CircleDNA genetic testing kits and subscription-based health insights. | Revenue comes from people paying for genetic health reports. |
| Diagnostic Services | Clinical and professional diagnostic screening services. | Revenue is earned from lab testing services for individuals and corporations. |
| Geography | Operations primarily in Hong Kong, Southeast Asia, and the UK. | Most revenue is derived from the Asia-Pacific region. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 296.01M | Price to Sales(TTM) 2.62 |
Enterprise Value 296.01M | Price to Sales(TTM) 2.62 | ||
Enterprise Value to Revenue 1.84 | Enterprise Value to EBITDA 0.14 | Shares Outstanding 15.20M | Shares Floating 12.79M |
Shares Outstanding 15.20M | Shares Floating 12.79M | ||
Percent Insiders 14.54 | Percent Institutions 7.88 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Prenetics Global Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2022-05-18 | Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 98 | Website https://www.prenetics.com |
Full time employees 98 | Website https://www.prenetics.com | ||
Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.